CG0006, a novel histone deacetylase inhibitor, induces breast cancer cell death via histone-acetylation and chaperone-disrupting pathways independent of ER status Hyun Mi KimChoung-Soo KimJene Choi Preclinical study 24 December 2010 Pages: 365 - 375
Significance of ER–Src axis in hormonal therapy resistance Sreeram VallabhaneniBinoj C. NairRatna K. Vadlamudi Preclinical study 24 December 2010 Pages: 377 - 385
Resveratrol suppresses growth of cancer stem-like cells by inhibiting fatty acid synthase Puspa R. PandeyHiroshi OkudaKounosuke Watabe Preclinical Study 29 December 2010 Pages: 387 - 398
P53 genotype as a determinant of ER expression and tamoxifen response in the MMTV-Wnt-1 model of mammary carcinogenesis Robin Fuchs-YoungStephanie H. ShirleyStephen D. Hursting Preclinical study 30 December 2010 Pages: 399 - 408
Gene expression profiling of luminal B breast cancers reveals NHERF1 as a new marker of endocrine resistance Thomas KarnEugen RuckhäberleAchim Rody Preclinical study 04 January 2011 Pages: 409 - 420
Struggling with subtypes: trying to bridge the gap between molecular breast cancer subtypes and clinical management Nadia Harbeck Invited commentary 08 April 2011 Pages: 421 - 423
A non-BRCA1/2 hereditary breast cancer sub-group defined by aCGH profiling of genetically related patients M. A. DidragaE. H. van BeersP. M. Nederlof Preclinical study 01 February 2011 Pages: 425 - 436
Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy Scott ThomasKenneth T. ThurnPamela N. Münster Preclinical study 05 February 2011 Pages: 437 - 447
Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients Cristina RaimondiAngela GradilonePaola Gazzaniga Preclinical study 05 February 2011 Pages: 449 - 455
Alpha- and beta-adrenergic receptor (AR) protein expression is associated with poor clinical outcome in breast cancer: an immunohistochemical study D. G. PoweM. J. VossF. Entschladen Preclinical study 06 February 2011 Pages: 457 - 463
IL-15 and IL-2 increase Cetuximab-mediated cellular cytotoxicity against triple negative breast cancer cell lines expressing EGFR M. P. RobertiM. M. BarrioE. M. Levy Preclinical study 10 February 2011 Pages: 465 - 475
Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy Sibylle LoiblBerit Maria MüllerCarsten Denkert Clinical trial 12 August 2011 Pages: 477 - 487
A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments Yahong WangQuangui YinYun Niu Clinical trial 12 August 2011 Pages: 489 - 498
Young age is associated with ipsilateral breast tumor recurrence after breast conserving surgery and radiation therapy in patients with HER2-positive/ER-negative subtype Hee Jeong KimWonshik HanDong-Young Noh Clinical trial 19 August 2011 Pages: 499 - 505
Lymph node ratio and pN staging in patients with node-positive breast cancer: a report from the Korean breast cancer society Sei Hyun AhnHee Jeong KimHo Yong Park Clinical Trial 21 August 2011 Pages: 507 - 515
Association between the p53 polymorphisms and breast cancer risk: meta-analysis based on case–control study Xiao-Feng HeJiao SuK. Arparkorn Epidemiology 22 May 2011 Pages: 517 - 529
Unmet supportive care needs: a cross-cultural comparison between Hong Kong Chinese and German Caucasian women with breast cancer Wendy W. T. LamAngel H. Y. AuAnja Mehnert Epidemiology 27 May 2011 Pages: 531 - 541
Effect of false-positives and women’s characteristics on long-term adherence to breast cancer screening R. RománM. SalaX. Castells Epidemiology 27 May 2011 Pages: 543 - 552
Age-specific trends of survival in metastatic breast cancer: 26 years longitudinal data from a population-based cancer registry in Stockholm, Sweden Theodoros FoukakisTommy FornanderJonas Bergh Epidemiology 27 May 2011 Pages: 553 - 560
Association between polymorphisms of the renin–angiotensin system genes and breast cancer risk: a meta-analysis Bo XiTao ZengJun Li Epidemiology 03 June 2011 Pages: 561 - 568
Androgens and musculoskeletal symptoms among breast cancer patients on aromatase inhibitor therapy Lisa GallicchioRyan MacDonaldKathy J. Helzlsouer Epidemiology 07 June 2011 Pages: 569 - 577
Long-term course of pain in breast cancer survivors: a 4-year longitudinal study Winfried RiefWayne A. BardwellJohn P. Pierce Epidemiology 09 June 2011 Pages: 579 - 586
Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger Mia M. GaudetMichael F. PressJonine L. Bernstein Epidemiology 11 June 2011 Pages: 587 - 597
Association of the germline TP53 R72P and MDM2 SNP309 variants with breast cancer survival in specific breast tumor subgroups Alexandra J. van den BroekAnnegien BroeksMarjanka K. Schmidt Epidemiology 11 June 2011 Pages: 599 - 608
Prognosis of metachronous contralateral breast cancer: importance of stage, age and interval time between the two diagnoses Voralak VichapatHans GarmoMargreet Lüchtenborg Epidemiology 14 June 2011 Pages: 609 - 618
Gene expression profile testing for breast cancer and the use of chemotherapy, serious adverse effects, and costs of care Jennifer S. HaasSu-Ying LiangKathryn A. Phillips Epidemiology 17 June 2011 Pages: 619 - 626
Correlation between docetaxel-induced skin toxicity and the use of steroids and H2 blockers: a multi-institution survey K. KawaguchiH. IshiguroJapan Breast Cancer Research Group (JBCRG) Epidemiology 23 June 2011 Pages: 627 - 634
Elevated PCNA+ tumor-associated macrophages in breast cancer are associated with early recurrence and non-Caucasian ethnicity Rita A. MukhtarAmy P. MooreLaura J. Esserman Epidemiology 30 June 2011 Pages: 635 - 644
CD8+ cytotoxic T cell and FOXP3+ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes Fangfang LiuRonggang LangLi Fu Epidemiology 30 June 2011 Pages: 645 - 655
COX-2 expression predicts worse breast cancer prognosis and does not modify the association with aspirin Michelle D. HolmesWendy Y. ChenRulla M. Tamimi Epidemiology 05 July 2011 Pages: 657 - 662
Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA Mark MackiewiczKonrad HuppiNatasha J. Caplen Brief Report 04 August 2011 Pages: 663 - 679
Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer Larissa NekhlyudovLingling LiAnita K. Wagner Brief Report 13 August 2011 Pages: 681 - 689
What can we learn from the age- and race/ethnicity- specific rates of inflammatory breast carcinoma? Dora Il’yasovaSharareh Siamakpour-ReihaniJoellen Schildkraut Brief Report 18 August 2011 Pages: 691 - 697
Predicting lymphatic drainage patterns and primary tumour location in patients with breast cancer Evan I. BlumgartRoger F. UrenHayley M. Reynolds Brief Report 18 August 2011 Pages: 699 - 705
Anti-cytokeratin CAM 5.2 (B.D. Biosciences) has a primary reactivity with CK 7 and CK 8 (48 and 52 kD) rather than with the smaller molecular weight keratin breakdown fractions (50, 43, and 38 kD) Chung-Chin YaoWea-Lung LinChih-Ping Han Letter to the Editor 22 June 2011 Pages: 707 - 708
A Halsted mastectomy 21 years before Halsted Gregory TsoucalasAntonis A. KousoulisGeorge Androutsos Letter to the Editor 05 July 2011 Pages: 709 - 710
